title: Whole abdominal irradiation for tumors of the uterine corpus.
abstract: Between November 1981 and December 1985, 16 patients with high-risk tumors of the uterine corpus were treated with a postoperative course of whole abdominal-pelvic irradiation. Thirteen patients had carcinomas and three had sarcomas. All patients had complete pelvic surgery including extrafascial (or modified radical) hysterectomy and bilateral salpingo-oophorectomy, pelvic node sampling, evaluation of peritoneal cytology, and resection of extrauterine metastases when indicated. All patients were free of gross visible tumor after surgery. Target doses of radiation were 3000 cGy to the upper abdomen and 4500 cGy to the pelvis. Median follow-up was 24 months for survivors (range, 17 to 63 months). The disease-free survival and overall survival at 17 months was 50%. Six of the 16 (38%) patients suffered intraabdominal relapse. One patient had a significant complication (bowel perforation). The data from this pilot study suggest that whole abdominal-pelvic irradiation may be useful only in the management of some patients with few high risk features of endometrial carcinoma. Patients with extensive extra-uterine involvement and with sarcoma histology do not appear to benefit from this experimental therapy.
authors.affiliation: Department of Radiation Therapy, Harvard Medical School, Boston, MA.
authors.forename: J S
authors.initials: JS
authors.lastname: Loeffler
authors.forename: E M
authors.initials: EM
authors.lastname: Rosen
authors.forename: J M
authors.initials: JM
authors.lastname: Niloff
authors.forename: A E
authors.initials: AE
authors.lastname: Howes
authors.forename: R C
authors.initials: RC
authors.lastname: Knapp
mesh_terms: D000005:Abdomen; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008207:Lymphatic Metastasis; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000401:mortality / Q000532:radiotherapy; D010315:Particle Accelerators; D010388:Pelvis; D011182:Postoperative Care; D011379:Prognosis; D011879:Radiotherapy Dosage; D014594:Uterine Neoplasms / Q000401:mortality / Q000532:radiotherapy*